Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

66.7%

2 terminated/withdrawn out of 3 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT05352217Terminated

The Possible Influence of Different Follow-up Modalities on Overall Survival in Ovarian Cancer

Role: lead

NCT05354973Recruiting

ePRO for the Timely Detection of Side Effects in Cancer Patients Undergoing CAR T Immunotherapy

Role: lead

NCT03578731Terminated

Efficacy of the "Consilium" Smartphone App for Detecting Symptoms and Treatment Side Effects in Cancer Patients

Role: collaborator

All 3 trials loaded